1-3 of 3
Vladimir Cmiljanovic
Close
Sort by
Journal Articles

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Petra Hillmann, Filippo Spriano, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Anastasios Stathis, Emanuele Zucca, Doriano Fabbro, Vladimir Cmiljanovic, Francesco Bertoni, MD
Journal: Blood
Blood (2016) 128 (22): 3017.
https://doi.org/10.1182/blood.V128.22.3017.3017
Published: 2016
Journal Articles

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Luciano Cascione, Elena Bernasconi, Petra Hillmann, Anastasios Stathis, MD, Georg Stussi, MD, Doriano Fabbro, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Blood
Blood (2015) 126 (23): 4005.
https://doi.org/10.1182/blood.V126.23.4005.4005
Published: 2015
Journal Articles

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, Matteo Stifanelli, Elena Bernasconi, B.Sc., Chiara Barassi, Petra Hillmann, Anastasios Stathis, MD, Laura Carrassa, Massimo Broggini, Georg Stussi, MD, Doriano Fabbro, Paul Hebeisen, Frances Betts, Andreas Wicki, Emanuele Zucca, MD, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Blood
Blood (2014) 124 (21): 1782.
https://doi.org/10.1182/blood.V124.21.1782.1782
Published: 2014